<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05079256</url>
  </required_header>
  <id_info>
    <org_study_id>LPA-01</org_study_id>
    <nct_id>NCT05079256</nct_id>
  </id_info>
  <brief_title>Laser Induced Changes to Innervation and Vascularisation of Psoriatic Skin</brief_title>
  <acronym>LPA-01</acronym>
  <official_title>A Preliminary Study on the Effect of Photothermal Laser Therapy on the Vascularization and Innervation of Psoriatic Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nick van der Beek</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>ZBC MultiCare</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The researchers investigate the effect of a treatment with selective photothermolysis using a&#xD;
      595 nm pulsed dye laser on the blood vessel density and the nerve fibre density of a&#xD;
      psoriatic lesion. Two lesions are selected, one undergoing deferred treatment so as to act as&#xD;
      a measure of normal disease progression and the other receiving laser therapy. By comparing&#xD;
      tissue samples collected before and after two treatments, the researchers determine the&#xD;
      relative effect of laser therapy on the (hyper)innervation of psoriatic skin.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Vascular laser therapy for psoriasis seems to achieve a remarkably long treatment-free&#xD;
      duration of remission. But why would sub-second heating of the blood vessels of the skin&#xD;
      result in a year-long resolution of an infamously stubborn condition?&#xD;
&#xD;
      Unraveling the mechanism of action of laser therapy would not only allow for the improvement&#xD;
      of existing laser therapy protocols but also, could open the door to a whole new range of&#xD;
      interventions offering quasi-permanent solutions for patients. There is a high need for such&#xD;
      enduring therapies: Psoriasis is both, a common and a costly skin condition. It affects&#xD;
      between 1% and 9% of the population and has a very severe impact on the quality of life of&#xD;
      the patient. It's chronic character implies lifelong treatment, and the associated risks and&#xD;
      effort&#xD;
&#xD;
      This project aims to assess the effect of laser therapy on the blood vessels and (peripheral)&#xD;
      innervation of psoriasis plaques. The primary objective is to quantify the regression and&#xD;
      recovery of nerves compared to blood vessels. The researchers hypothesize that the recovery&#xD;
      of nerves after Selective Photo Thermolysis (SPT) is decreased compared to the recovery of&#xD;
      blood vessels.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2021</start_date>
  <completion_date type="Anticipated">November 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>single blinded randomized intra-patient comparison</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>tissue samples are described using random pre-assigned codes.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Recovery ration</measure>
    <time_frame>6 months.</time_frame>
    <description>Relative change in the ratio of the linear nerve density and linear blood vessel density.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recovery ratio vs lymphocyte infiltration</measure>
    <time_frame>6 months</time_frame>
    <description>Correlation between change in the ratio of the linear nerve density and linear blood vessel density versus change in number of infiltrating lymphocytes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical improvement</measure>
    <time_frame>6 months</time_frame>
    <description>Change in severity determined using a visual-analogue scale.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Psoriasis Vulgaris</condition>
  <arm_group>
    <arm_group_label>Laser therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>595 nm Pulsed dye laser (PDL) therapy for psoriasis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>deferred treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Untreated lesion</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>595 nm Pulsed dye laser (Candela V-beam perfecta)</intervention_name>
    <description>595 nm pulsed dye laser therapy. 2 treatments Fluence ~ 6 - 9 J/cm^2 Pulse duration ~ 0.45 - 3.0 ms 33% overlap.</description>
    <arm_group_label>Laser therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 - 69 years of age&#xD;
&#xD;
          -  Psoriasis vulgaris&#xD;
&#xD;
          -  Skin type I - III&#xD;
&#xD;
          -  Minimal surface of lesion of 3 cm2&#xD;
&#xD;
          -  Contralateral psoriasis vulgaris lesions located on chest, back, or upper legs&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
        A potential subject who meets any of the following criteria will be excluded from&#xD;
        participation in this study if:&#xD;
&#xD;
          -  The participant uses other treatments (than laser therapy) during the study or two&#xD;
             weeks before the start of the study that are known to affect psoriasis&#xD;
&#xD;
          -  The participant suffers from any known neurological, vascular, or immunological&#xD;
             condition other than psoriasis.&#xD;
&#xD;
          -  The participant is allergic to lidocaine&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nick van der Beek, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>ZBC MultiCare</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nick van der Beek, Ph.D</last_name>
    <phone>+31356249576</phone>
    <email>Clinical_Research@zbcmulticare.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>ZBC MultiCare</name>
      <address>
        <city>Hilversum</city>
        <state>Noord-Holland</state>
        <zip>1217AB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>https://zbcmulticare.nl/lasering-psoriasis-away/</url>
    <description>This investigation is part of a larger research collaboration, more information on which can be found at the website mentioned above.</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 20, 2021</study_first_submitted>
  <study_first_submitted_qc>October 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 15, 2021</study_first_posted>
  <last_update_submitted>October 14, 2021</last_update_submitted>
  <last_update_submitted_qc>October 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>ZBC MultiCare</investigator_affiliation>
    <investigator_full_name>Nick van der Beek</investigator_full_name>
    <investigator_title>Managing director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
    <mesh_term>Neovascularization, Pathologic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

